U.S. Markets open in 7 hrs 3 mins

BioLine Rx Ltd (BLRX)

NASDAQ Capital Market - NASDAQ Capital Market Delayed Price. Currency in USD
Add to watchlist
1.025-0.075 (-6.818%)
At close: 3:59PM EDT
People also watch
CANFCPRXPLXANTHAVEO
  • D
    David
    David
    Even Stevie Wonder could have seen this coming

    Back to .87, may take a month or two but, it will happen
  • G
    Gary
    Gary
    ok, tell me what the bad news is today for blrx? crazy market ..
  • g
    guy
    guy
    Hold tight friends ... I feel it coming and it will be a powerful move up
  • B
    BioNap
    BioNap

    SLNO (MC $18 M) BLOCKBUSTER in Phase 3 /Rare Disease & Orphan Status = Undiscovered low float stock with 1000% upside Potential and more .GLTA

    Soleno therapeutics (SLNO)

    Market Cap $18 Million
    Cash: $8 Million
    Price $0.37

    Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)

    Initiating Coverage June 26, 2017
    http://www.lifescicapital.com/wp-content/uploads/Soleno.pdf

    •Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.

    Market Opportunity for PWS is Substantial.

    While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE)
    Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.

  • r
    ryan
    ryan
    weak hands step to the side and miss out
  • D
    David
    David
    Buy some shares Phil, before we are back to .87
  • D
    David
    David
    Buy some shares Phil
  • A
    Alfredo
    Alfredo
    Title of #$%$ even this ..... the biopharm is just a scam !!!
  • f
    francis
    francis
    Any more good news to drive SP higher or down it will go?
  • s
    sykohawk
    sykohawk
    any idea besides 2H2017, when Phase 3 trials will begin?
  • D
    David
    David
    And so the slow descend to .87 continues until years end when we can only hope Keytruda will be good for BL8040

    If not, there is nothing for the next 18 months that will help bolster the share price
  • A
    Alfredo
    Alfredo
    IL SETTORE BIO è SOLO UNA TRUFFA PER RUBARE SOLDI!!!!
  • c
    corey walz
    corey walz
    Right now I just want to see 10 days above $1 and then I think we'll break a resistance point and hopefully end up around 1.25 or 1.30 (dreaming probably) after the positive earnings come out
  • D
    David
    David
    Phil - You must be ready to resign by now?
    You suk and must totally feel inept watching the market soar higher while BLRX remains in the dumper
  • D
    David
    David
    Be a man Phil you waste and buy some shares!
  • S
    Savannah
    Savannah
    In the short-term BLRX does not seem to be like a good trade. This is so frustrating trying to find trade ideas. I've subscribed to some email newsletters which helps me with new stock ideas. awesom_sto-cks is the one i like best.
  • T
    Tron II
    Tron II
    Check out OXIS, about to run hard. New management from Pfizer and Chase Pharma. Do your dd.
  • H
    Hansen Teng
    Hansen Teng
    Check out OMER value. BLRX does not show any progress of its pipeline of drug candidates since 2012, which is the only weak spot I can tell.
  • B
    BobDole
    BobDole
    Lookn' to buy in 1.10 range or lower. Seems to have a good story to it. Results by end of year or early next year + new capital with strike price in $2 range + low cash burn rate.
  • D
    David
    David
    Regurgitated info by our illustrious CEO, Phildo. Buy some shares Phildo